Advertisement

Science Journal Calls Cancer Immunotherapy the Year's Top Advance — Physician’s First Watch

Medical News |
December 20, 2013

Science Journal Calls Cancer Immunotherapy the Year's Top Advance

By the Editors

Using the word "breakthrough" causes anxiety and hives to break out here in the newsroom, but we must report that Science has conferred "Breakthrough of the Year" status to cancer immunotherapy.

That journal's editors wonder whether they risk hyping something "that has touched a tiny fraction of cancer patients and helped only some of them." Nonetheless, they describe a research approach that started over 25 years ago that, expressed in simple terms, takes the brakes off the patient's immune system that had prevented it from "launching full-out immune attacks."

Even though the trials have been limited, for physicians treating patients with advanced disease, the results "bring a hope they couldn't have fathomed a few years ago."

Bravo.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement